You can see the numbers by sex, age, race and ethnicity, trends over time, survival, and prevalence.Link: https://gis.cdc.gov/Cancer/USCS/#/AtAGlance

Analysis of ‘🎗️ Cancer Rates by U.S. State’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/yamqwe/cancer-rates-by-u-s-statee on 13 February 2022.

--- Dataset description provided by original source is as follows ---

About this dataset

In the following maps, the U.S. states are divided into groups based on the rates at which people developed or died from cancer in 2013, the most recent year for which incidence data are available.

The rates are the numbers out of 100,000 people who developed or died from cancer each year.

Incidence Rates by State
The number of people who get cancer is called cancer incidence. In the United States, the rate of getting cancer varies from state to state.

• *Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.

• ‡Rates are not shown if the state did not meet USCS publication criteria or if the state did not submit data to CDC.

• †Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016. Available at: http://www.cdc.gov/uscs.

Death Rates by State
Rates of dying from cancer also vary from state to state.

• *Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.

• †Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016. Available at: http://www.cdc.gov/uscs.

Source: https://www.cdc.gov/cancer/dcpc/data/state.htm

This dataset was created by Adam Helsinger and contains around 100 samples along with Range, Rate, technical information and other features such as: - Range - Rate - and more.

How to use this dataset

• Analyze Range in relation to Rate
• Study the influence of Range on Rate
• More datasets

Acknowledgements

If you use this dataset in your research, please credit Adam Helsinger

Start A New Notebook!

--- Original source retains full ownership of the source dataset ---

The State Cancer Profiles (SCP) web site provides statistics to help guide and prioritize cancer control activities at the state and local levels. SCP is a collaborative effort using local and national level cancer data from the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology and End Results Registries (SEER). SCP address select types of cancer and select behavioral risk factors for which there are evidence-based control interventions. The site provides incidence, mortality and prevalence comparison tables as well as interactive graphs and maps and support data. The graphs and maps provide visual support for deciding where to focus cancer control efforts.

Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

This map service portrays the number of deaths per 100,000 people per square mile from lung and colon cancer. It displays the distribution of lung and colon cancer across the United States. Pop-ups show attributes such as state name, county name, number of colon or lung cancer deaths, and square miles per area.Lung Cancer: Death due to malignant neoplasm of the trachea, bronchus and lung.Colon Cancer: Death due to malignant neoplasm of the colon, rectum and anus.This data was sourced from: Community Health Status Indicators_Other Health Datapalooza focused content that may interest you: Health Datapalooza Health Datapalooza

This web map is part of the Centers for Disease Control and Prevention (CDC) PLACES. It provides model-based estimates of colorectal cancer screening prevalence among adults aged 50-75 years at county, place, census tract and ZCTA levels in the United States. PLACES is an expansion of the original 500 Cities Project and a collaboration between the CDC, the Robert Wood Johnson Foundation, and the CDC Foundation. Data sources used to generate these estimates include the Behavioral Risk Factor Surveillance System (BRFSS), Census 2020 population counts or Census annual county-level population estimates, and the American Community Survey (ACS) estimates. For detailed methodology see www.cdc.gov/places. For questions or feedback send an email to places@cdc.gov.Measure name used for colorectal cancer screening is COLON_SCREEN.

This dataset contains Cancer Incidence data for Breast Cancer (All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for females segmented by age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

Note: Not able to update for 2024 release (2022 estimates). This web map is part of the Centers for Disease Control and Prevention (CDC) PLACES. It provides model-based estimates of cervical cancer screening prevalence among women aged 21-65 years at county, place, census tract and ZCTA levels in the United States. PLACES is an expansion of the original 500 Cities Project and a collaboration between the CDC, the Robert Wood Johnson Foundation, and the CDC Foundation. Data sources used to generate these estimates include the Behavioral Risk Factor Surveillance System (BRFSS), Census 2010 population counts or Census annual county-level population estimates, and the American Community Survey (ACS) estimates. For detailed methodology see www.cdc.gov/places. For questions or feedback send an email to places@cdc.gov.Measure name used for cervical cancer screening is CERVICAL.

This dataset contains model-based county-level estimates for the PLACES 2021 release in GIS-friendly format. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. Project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2019 or 2018 county population estimates, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS data because the relevant questions are only asked every other year in the BRFSS. These data can be joined with the census 2015 county boundary file in a GIS system to produce maps for 29 measures at the county level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=024cf3f6f59e49fe8c70e0e5410fe3cf

This dataset contains model-based county-level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. Project was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2021 or 2020 county population estimates, and American Community Survey (ACS) 2017–2021 or 2016–2020 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the census 2020 county boundary file in a GIS system to produce maps for 36 measures at the county level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588

This is one of four collections of cancer rate maps by ZIP code in New York State published in 2000 (breast, colorectal, lung) and 2001 (prostate) by the New York State Department of Health as part of the Cancer Surveillance Improvement Initiative. At some point they were removed from the public web site and do not appear to have been otherwise archived online.

This dataset contains model-based census tract level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the census tract 2015 boundary file in a GIS system to produce maps for 36 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588

This is one of four collections of cancer rate maps by ZIP code in New York State published in 2000 (breast, colorectal, lung) and 2001 (prostate) by the New York State Department of Health as part of the Cancer Surveillance Improvement Initiative. At some point they were removed from the public web site and do not appear to have been otherwise archived online.

This dataset contains model-based place (incorporated and census designated places) estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia —at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the 2019 Census TIGER/Line place boundary file in a GIS system to produce maps for 36 measures at the place level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588

Radon, a naturally occurring radioactive gas, is the second leading cause of lung cancer after tobacco smoke and the leading cause of lung cancer in nonsmokers in the United States. Radon is an under-recognized health concern in Alaska. This online map serves as a guide to where radon may occur; however, indoor radon concentrations can vary greatly from building to building. The only way to know if your home contains radon is to test. More information is available at http://dggs.alaska.gov/hazards/radon.html.The State of Alaska, Division of Geological & Geophysical Surveys is growing an Alaska Radon Database that contains radon test results from buildings located in communities all over the State. This map contains four layers of hexagons displaying test-result statistics at the scales of 1,024, 256, 64, and 16 square kilometers. These layers display in turn as you zoom into the map. Hexagons are colored based on the average (mean) of the indoor-air radon test results that are located in each hexagon. Where multiple test results are available at an individual test location (building), the maximum value is used. As of September 30, 2019, test results were available for 1,737 individual buildings statewide. Hexagons containing fewer than 10 results are labelled with “LC”, meaning “Low Count”. Hexagons may be selected to show additional statistics.The map also contains a radon-potential layer modeled from available test results and three statewide datasets, uranium in soils and sediments, depth to water table (and permafrost), and geology. More information about this layer will be available in forthcoming metadata. This map should not be used to determine whether to test your home. No matter where you live, test your home for radon. Buildings located in any radon-potential zone may concentrate radon gas, leading to significant levels of indoor radon at that site.This web map is included in the following web app: https://geoportal.dggs.dnr.alaska.gov/portal/home/item.html?id=8ed4e400e2d9460c8cf959deb91ee22b

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths in the United States. The purpose of this study was to evaluate the gene expression differences in different stages of CRC. Gene expression data on 433 CRC patient samples were obtained from The Cancer Genome Atlas (TCGA). Gene expression differences were evaluated across CRC stages using linear regression. Genes with p≤0.001 in expression differences were evaluated further in principal component analysis and genes with p≤0.0001 were evaluated further in gene set enrichment analysis. A total of 377 patients with gene expression data in 20,532 genes were included in the final analysis. The numbers of patients in stage I through IV were 59, 147, 116 and 55, respectively. NEK4 gene, which encodes for NIMA related kinase 4, was differentially expressed across the four stages of CRC. The stage I patients had the highest expression of NEK4 genes, while the stage IV patients had the lowest expressions (p = 9*10−6). Ten other genes (RNF34, HIST3H2BB, NUDT6, LRCh4, GLB1L, HIST2H4A, TMEM79, AMIGO2, C20orf135 and SPSB3) had p value of 0.0001 in the differential expression analysis. Principal component analysis indicated that the patients from the 4 clinical stages do not appear to have distinct gene expression pattern. Network-based and pathway-based gene set enrichment analyses showed that these 11 genes map to multiple pathways such as meiotic synapsis and packaging of telomere ends, etc. Ten of these 11 genes were linked to Gene Ontology terms such as nucleosome, DNA packaging complex and protein-DNA interactions. The protein complex-based gene set analysis showed that four genes were involved in H2AX complex II. This study identified a small number of genes that might be associated with clinical stages of CRC. Our analysis was not able to find a molecular basis for the current clinical staging for CRC based on the gene expression patterns.

We have developed ProjecTILs, a computational approach to project new data sets into a reference map of T cells, enabling their direct comparison in a stable, annotated system of coordinates. Because new cells are embedded in the same space of the reference, ProjecTILs enables the classification of query cells into annotated, discrete states, but also over a continuous space of intermediate states. By comparing multiple samples over the same map, and across alternative embeddings, the method allows exploring the effect of cellular perturbations (e.g. as the result of therapy or genetic engineering) and identifying genetic programs significantly altered in the query compared to a control set or to the reference map. We illustrate the projection of several data sets from recent publications over two cross-study murine T cell reference atlases: the first describing tumor-infiltrating T lymphocytes (TILs), the second characterizing acute and chronic viral infection.To construct the reference TIL atlas, we obtained single-cell gene expression matrices from the following GEO entries: GSE124691, GSE116390, GSE121478, GSE86028; and entry E-MTAB-7919 from Array-Express. Data from GSE124691 contained samples from tumor and from tumor-draining lymph nodes, and were therefore treated as two separate datasets. For the TIL projection examples (OVA Tet+, miR-155 KO and Regnase-KO), we obtained the gene expression counts from entries GSE122713, GSE121478 and GSE137015, respectively.Prior to dataset integration, single-cell data from individual studies were filtered using TILPRED-1.0 (https://github.com/carmonalab/TILPRED), which removes cells not enriched in T cell markers (e.g. Cd2, Cd3d, Cd3e, Cd3g, Cd4, Cd8a, Cd8b1) and cells enriched in non T cell genes (e.g. Spi1, Fcer1g, Csf1r, Cd19). Dataset integration was performed using STACAS (https://github.com/carmonalab/STACAS), a batch-correction algorithm based on Seurat 3. For the TIL reference map, we specified 600 variable genes per dataset, excluding cell cycling genes, mitochondrial, ribosomal and non-coding genes, as well as genes expressed in less than 0.1% or more than 90% of the cells of a given dataset. For integration, a total of 800 variable genes were derived as the intersection of the 600 variable genes of individual datasets, prioritizing genes found in multiple datasets and, in case of draws, those derived from the largest datasets. We determined pairwise dataset anchors using STACAS with default parameters, and filtered anchors using an anchor score threshold of 0.8. Integration was performed using the IntegrateData function in Seurat3, providing the anchor set determined by STACAS, and a custom integration tree to initiate alignment from the largest and most heterogeneous datasets.Next, we performed unsupervised clustering of the integrated cell embeddings using the Shared Nearest Neighbor (SNN) clustering method implemented in Seurat 3 with parameters {resolution=0.6, reduction=”umap”, k.param=20}. We then manually annotated individual clusters (merging clusters when necessary) based on several criteria: i) average expression of key marker genes in individual clusters; ii) gradients of gene expression over the UMAP representation of the reference map; iii) gene-set enrichment analysis to determine over- and under- expressed genes per cluster using MAST. In order to have access to predictive methods for UMAP, we recomputed PCA and UMAP embeddings independently of Seurat3 using respectively the prcomp function from basic R package “stats”, and the “umap” R package (https://github.com/tkonopka/umap).

This map service displays all air-related layers used in the USEPA Community/Tribal-Focused Exposure and Risk Screening Tool (C/T-FERST) mapping application (http://cfpub.epa.gov/cferst/index.cfm). The following data sources (and layers) are contained in this service: USEPA's 2005 National-Scale Air Toxic Assessment (NATA) data. Data are shown at the census tract level (2000 census tract boundaries, US Census Bureau) for Cumulative Cancer and Non-Cancer risks (Neurological and Respiratory) from 139 air toxics. In addition, individual pollutant estimates of Ambient Concentration, Exposure Concentration, Cancer, and Non-Cancer risks (Neurological and Respiratory) are provided for: Acetaldehyde, Acrolein, Arsenic, Benzene, 1,3-Butadiene, Chromium, Diesel PM, Formaldehyde, Lead, Naphthalene, and Polycyclic Aromatic Hydrocarbon (PAH). The original Access tables were downloaded from USEPA's Office of Air and Radiation (OAR) http://www.epa.gov/ttn/atw/nata2005/tables.html. The data classification (defined interval) for this map service was developed for USEPA's Office of Research and Development's (ORD) Community-Focused Exposure and Risk Screening Tool (C-FERST) per guidance provided by OAR. The 2005 NATA provides information on 177 of the 187 Clean Air Act air toxics (http://www.epa.gov/ttn/atw/nata2005/05pdf/2005polls.pdf) plus diesel particulate matter (diesel PM was assessed for non-cancer only). For additional information about NATA, go to http://www.epa.gov/ttn/atw/nata2005/05pdf/nata_tmd.pdf or contact Ted Palma, USEPA (palma.ted@epa.gov). NATA data disclaimer: USEPA strongly cautions that these modeling results are most meaningful when viewed at the state or national level, and should not be used to draw conclusions about local exposures or risks (e.g., to compare local areas, to identify the exact location of "hot spots", or to revise or design emission reduction programs). Substantial uncertainties with the input data for these models may cause the results to misrepresent actual risks, especially at the census tract level. However, we believe the census tract data and maps can provide a useful approximation of geographic patterns of variation in risk within counties. For example, a cluster of census tracts with higher estimated risks may suggest the existence of a "hot spot," although the specific tracts affected will be uncertain. More refined assessments based on additional data and analysis would be needed to better characterize such risks at the tract level. (http://www.epa.gov/ttn/atw/nata2005/countyxls/cancer_risk02_county_042009.xls). Note that these modeled estimates are derived from outdoor sources only; indoor sources are not included in these examples, but may be significant in some cases. The modeled exposure estimates are for a median individual in the geographic area shown. Note that in some cases the estimated relationship between human exposure and health effect may be calculated as a high end estimate, and thus may be more likely to overestimate than underestimate actual health effects for the median individual in the geographic area shown. Other limitations to consider when looking at the results are detailed on the EPA 2005 NATA website. For these reasons, the NATA maps included in C-FERST are provided for screening purposes only. See the 2005 National Air Toxic Assessment website for recommended usage and limitations on the estimated cancer and noncancer data provided above. USEPA's NonAttainment areas data. C-FERST displays Ozone for 8-hour Ozone based on the 1997 standard for reporting and Particulate Matter PM-2.5 based on the 2006 standard for reporting. These are areas of the country where air pollution levels consistently exceed the national ambient air quality standards. Details about the USEPA's NonAttainment data are available at http://www.epa.gov/airquality/greenbook/index.html. Center of Disease Control's (CDC) Environmental Public Health Tracking (EPHT) data. Averaged over three years (2004 - 2006). The USEPA's ORD calculated a three-year average (2004 - 2006) using the values for Ozone (number of days with the maximum 8-hour average above the National Ambient Air Quality Standards (NAAQS)) and PM 2.5 (annual ambient concentration). These data were extracted by the CDC from the USEPA's ambient air monitors and are displayed at the county level. USEPA received the Monitor and Modeled data from the CDC and calculated the three year average displayed in the web service. For more details about the CDC EPHT data, go to http://ephtracking.cdc.gov/showHome.action.

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2021 or 2020 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2023 release uses 2021 BRFSS data for 29 measures and 2020 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours) that the survey collects data on every other year. These data can be joined with the census 2010 ZCTA boundary file in a GIS system to produce maps for 36 measures at the ZCTA level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=2c3deb0c05a748b391ea8c9cf9903588

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates for the PLACES 2021 release in GIS-friendly format. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS data because the relevant questions are only asked every other year in the BRFSS. These data can be joined with the census 2010 ZCTA boundary file in a GIS system to produce maps for 29 measures at the ZCTA level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=024cf3f6f59e49fe8c70e0e5410fe3cf